TY  - GEN
AU  - Magenau,J
AU  - Westervelt,P
AU  - Khaled,S
AU  - McGuirk,J
AU  - Hari,P
AU  - Eapen,M
AU  - Becker,P S
AU  - Parkin,B
AU  - Braun,T
AU  - Logan,B
AU  - Wang,H
AU  - Jagasia,M
AU  - Rowley,S D
AU  - Kim,D D H
AU  - Schechter,T
AU  - Frey,N
AU  - Scott,B
AU  - Churay,T
AU  - Lieland,S
AU  - Forman,S
AU  - Mineishi,S
TI  - A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation
SN  - 1476-5365
PY  - 2017///1214
KW  - Adenine Nucleotides
KW  - administration & dosage
KW  - Adult
KW  - Aged
KW  - Allografts
KW  - Arabinonucleosides
KW  - Busulfan
KW  - Clofarabine
KW  - Disease-Free Survival
KW  - Female
KW  - Hematopoietic Stem Cell Transplantation
KW  - Humans
KW  - Induction Chemotherapy
KW  - Leukemia, Myeloid, Acute
KW  - mortality
KW  - Male
KW  - Middle Aged
KW  - Survival Rate
KW  - Transplantation Conditioning
N1  - Publication Type: Clinical Trial; Journal Article; Multicenter Study
UR  - https://doi.org/10.1038/bmt.2016.188
ER  -